FIELD Study: Fenofibrate in T2DM
The Lancet (2005)
Reduced diabetic retinopathy progression by 37% and peripheral revascularization by 38% in 9,795 T2DM patients.
Fenofibrate
Oral tablet (145mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
FenofibrateFenofibrate
PPAR-alpha agonist for hypertriglyceridemia and mixed dyslipidemia. Reduces microvascular complications in T2DM (retinopathy 37% reduction in FIELD trial). Also has uricosuric effects. Preferred fibrate with statins (lower myopathy risk vs gemfibrozil).
TG reduction 30 to 50%
HDL-C increase 10 to 20%
Diabetic retinopathy reduction 37% (FIELD)
Uricosuric effect reduces gout risk
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Activates PPAR-alpha in hepatocytes and muscle, upregulating lipoprotein lipase and fatty acid oxidation genes. Increases triglyceride clearance, reduces VLDL production, raises HDL-C, and shifts LDL to large-buoyant particles.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Fenofibrate.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- GI upset
- Myalgia
- Elevated transaminases
- Elevated creatinine (reversible artifact)
- Photosensitivity
Less common but serious risks
- Cholelithiasis
- Myopathy/rhabdomyolysis (rare, increased with statin)
- DVT/PE (FIELD trial signal)
Generally not appropriate for
- Severe renal impairment
- Active liver disease
- Pre-existing gallbladder disease
- Gemfibrozil combination
- Pregnancy
Typical monitoring
- Lipid panel
- Liver function
- Serum creatinine/eGFR
- CK if myalgia
- Uric acid
FAQ
Quick answers.
PPAR-alpha agonist for hypertriglyceridemia and mixed dyslipidemia. Reduces microvascular complications in T2DM (retinopathy 37% reduction in FIELD trial). Also has uricosuric effects. Preferred fibrate with statins (lower myopathy risk vs gemfibrozil).
TG reduction 30 to 50%. HDL-C increase 10 to 20%. Diabetic retinopathy reduction 37% (FIELD). Uricosuric effect reduces gout risk. Safe with statins (preferred over gemfibrozil).
Common side effects include: gi upset, myalgia, elevated transaminases, elevated creatinine (reversible artifact), photosensitivity. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
PPAR-alpha agonist for hypertriglyceridemia and mixed dyslipidemia. Reduces microvascular complications in T2DM (retinopathy 37% reduction in FIELD trial). Also has uricosuric effects. Preferred fibrate with statins (lower myopathy risk vs gemfibrozil).
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.